Shots:

• The P-III CheckMate -227 Part 1a study involves assessing of Opdivo + Yervoy vs platinum-doublet CT in patients with 1L advanced NSCLC across non-squamous and squamous tumor expressing PD-L1 ≥1%
• The P-III Checkmate -227 Part 1a study resulted in meeting its 1EPs of overall survival. BMS also announced that Part 2 of CheckMate -227 study evaluating Opdivo plus CT- did not meet its 1EPs of OS in patients with 1L non-sq NSCLC regardless of PD-L1 status
• Opdivo is a PD-1 immune checkpoint inhibitor harnessing the body’s own immune system to restore anti-tumor immune response- indicated as monothx. or in combination with Yervoy to treat multiple cancer

Click here- Click here to­ read full press release/ article |

Ref: BMS | Image: BMS